Lantheus’ (LNTH) Neutral Rating Reiterated at Mizuho

Mizuho reaffirmed their neutral rating on shares of Lantheus (NASDAQ:LNTH) in a research note issued to investors on Tuesday morning, MarketBeat Ratings reports. The brokerage currently has a $109.00 price objective on the medical equipment provider’s stock, down from their prior price objective of $115.00.

Several other research analysts also recently weighed in on the stock. Brookline Capital Markets downgraded shares of Lantheus from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 28th. Weiss Ratings raised shares of Lantheus from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, September 25th. B. Riley Financial cut Lantheus from a “buy” rating to a “hold” rating in a report on Monday, August 17th. William Blair set a $102.50 price objective on Lantheus in a report on Monday, August 3rd. Finally, Truist Financial lowered Lantheus from a “buy” rating to a “hold” rating and cut their price objective for the stock from $125.00 to $102.50 in a research note on Monday, August 3rd. Three research analysts have rated the stock with a Buy rating and eleven have given a Hold rating to the company’s stock. According to MarketBeat.com, Lantheus presently has an average rating of “Hold” and a consensus price target of $107.44.

Lantheus Price Performance

Lantheus stock opened at $99.99 on Tuesday. The company’s fifty day moving average price is $100.40 and its 200 day moving average price is $97.71. Lantheus has a 1 year low of $50.15 and a 1 year high of $111.86. The stock has a market capitalization of $6.53 billion, a P/E ratio of 20.08 and a beta of -0.06. The company has a debt-to-equity ratio of 0.43, a quick ratio of 2.89 and a current ratio of 3.06.

Lantheus (NASDAQ:LNTH) last issued its quarterly earnings results on Thursday, August 6th. The medical equipment provider reported $1.55 EPS for the quarter, topping the consensus estimate of $1.30 by $0.25. The company had revenue of $388.18 million during the quarter, compared to analyst estimates of $363.23 million. Lantheus had a net margin of 17.69% and a return on equity of 28.10%. The firm’s revenue was up 2.7% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $1.57 EPS. As a group, equities research analysts anticipate that Lantheus will post 4.54 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Lantheus

A number of hedge funds have recently modified their holdings of LNTH. Jupiter Topco LLC acquired a new position in Lantheus during the second quarter worth about $575,628,000. ABS Investment Management LLC purchased a new stake in Lantheus during the 2nd quarter valued at about $232,974,000. Reinhart Partners LLC. grew its stake in Lantheus by 2.2% during the 2nd quarter. Reinhart Partners LLC. now owns 1,599,379 shares of the medical equipment provider’s stock valued at $177,437,000 after acquiring an additional 34,501 shares in the last quarter. Carmignac Gestion raised its holdings in Lantheus by 0.9% in the 2nd quarter. Carmignac Gestion now owns 1,340,100 shares of the medical equipment provider’s stock valued at $148,671,000 after acquiring an additional 12,100 shares during the last quarter. Finally, Assenagon Asset Management S.A. raised its holdings in Lantheus by 440.3% in the 2nd quarter. Assenagon Asset Management S.A. now owns 714,980 shares of the medical equipment provider’s stock valued at $79,320,000 after acquiring an additional 582,661 shares during the last quarter. 99.06% of the stock is currently owned by institutional investors and hedge funds.

About Lantheus

Lantheus Holdings, Inc (NASDAQ: LNTH) is a healthcare company that develops, manufactures and commercializes diagnostic and therapeutic products, with a focus on medical imaging and radiopharmaceuticals. Its products are used by physicians and healthcare providers to help detect, characterize and monitor disease.

The company’s portfolio includes PYLARIFY (piflufolastat F 18), a positron emission tomography imaging agent used to identify prostate-specific membrane antigen-positive lesions in men with prostate cancer, and DEFINITY, an ultrasound-enhancing agent used to improve cardiac ultrasound imaging.